Latest Regulatory Approval News

Promisia Healthcare is set to acquire Chatswood Retirement Village in Christchurch for $25 million, bolstering its East Christchurch presence and promising immediate earnings accretion.

Infinity Metals has locked in an exclusive option to acquire 100% of the Tule Canyon molybdenum-copper project in Nevada, a historically explored porphyry deposit with promising drill results and strategic positioning amid soaring molybdenum prices.

Heavy Rare Earths Limited (ASX:HRE) has secured $2.028 million through a placement and entitlement offer to advance drilling programs and a strategic review across its key projects in South Australia and Western Australia.

Strata Minerals is pushing forward multiple technical workstreams at its Zelica Gold Project in Western Australia, backed by BML Ventures. These initiatives aim to de-risk mine planning, processing, and permitting as the project moves closer to development.

Cygnus Metals has lodged its draft scheme booklet with ASIC, moving closer to a planned acquisition by Central Asia Metals. Regulatory approvals in North Macedonia are complete, with Kazakhstan clearance still pending.

RUA GOLD has obtained regulatory approval to start exploration drilling at its Glamorgan Project, a promising epithermal gold target adjacent to a major OceanaGold deposit in New Zealand. The company plans a 9,000-metre drill program to test three high-priority targets identified through extensive geophysical and geochemical surveys.

Pinnacle Investment Management delivered a 31.5% jump in net profit after tax to $176.7 million for FY26, boosted by full ownership of Pacific Asset Management and strong inflows across retail, institutional, and international channels.

WA Gold's latest assays from seven diamond drill holes at Abercromby reinforce the continuity of a high-grade gold system over 500m, underpinning a promising resource development phase.

CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Aldoro Resources has boosted the Kameelburg rare earth project’s Mineral Resource Estimate to 804.5 million tonnes, now hosting 1.37 million tonnes of contained NdPr oxide; exceeding key western-world deposits. The maiden Indicated Resource and robust metallurgical testwork set the stage for development.